BI 891065 + ezabenlimab

**BI 891065 + ezabenlimab** is an investigational combination therapy composed of two agents: BI 891065, an orally available small molecule mimetic of SMAC (Second Mitochondria-derived Activator of Caspases) that inhibits the Inhibitor of Apoptosis (IAP) proteins, and ezabenlimab (BI 754091), an anti-PD-1 monoclonal antibody immune checkpoint inhibitor. The combination is intended to potentiate apoptosis in tumor cells and to enhance anti-tumor immune response, aiming to leverage the synergistic effects of IAP inhibition and PD-1-mediated immune checkpoint blockade. It is developed primarily for the treatment of advanced or metastatic solid tumors, particularly in oncology settings, and has been evaluated in phase 1 clinical trials to determine safety, tolerability, and optimal dosing[2][5][1][3][4][7].

Other names

BI 891065 + BI 754091